Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Placebo injection

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,620 result(s) found for: Placebo injection. Displaying page 26 of 181.
    «« First « Previous 22  23  24  25  26  27  28  29  30  Next» Last»»
    EudraCT Number: 2020-005149-18 Sponsor Protocol Number: 033 Start Date*: 2021-04-26
    Sponsor Name:Medical University of Vienna
    Full Title: Preclinical antiplatelet treatment with Cangrelor in patients presenting with ST-Elevation myocardial infarction: a randomized, double-blind, placebo-controlled pilot trial
    Medical condition: ST-Elevation Myocardial Infarction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003890-20 Sponsor Protocol Number: 03661447 Start Date*: 2007-11-09
    Sponsor Name:Vejle Hospital
    Full Title: Postoperativ smertebehandling efter total hoftealloplastik Et randomiseret, dobbeltblindet og placebo-kontrolleret studie til vurdering af effekten af lokalanalgesi
    Medical condition: Postoperativ smertebehandling efter total hoftealloplastik
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054711 Postoperative pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002448-21 Sponsor Protocol Number: ACTIVATEII Start Date*: 2020-05-26
    Sponsor Name:Hellenic Institute for the Study of Sepsis
    Full Title: A RANDOMIZED CLINICAL TRIAL FOR ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT INFECTIONS ΒΥ COVID-19: THE ACTIVATE II TRIAL
    Medical condition: Prevention of COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10036897 Prophylactic vaccination LLT
    20.0 100000004865 10046859 Vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014835-19 Sponsor Protocol Number: CAIN457C2301 Start Date*: 2010-02-15
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio Fase III, multicéntrico, aleatorizado con doble enmascaramiento, controlado con placebo, de determinación de dosis y 24 semanas de duración, con el objetivo de evaluar el AIN457 frente a pl...
    Medical condition: Demostrar la eficacia y seguridad de AIN457 como terapia adyuvante en el tratamiento de la uveitis intermedia, uveitis posterior o panuveitis que precise inmunosupresión sistémica.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10022941 Iridocyclitis LLT
    9 10022557 Intermediate uveitis LLT
    9 10033687 Panuveitis LLT
    9 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003191-50 Sponsor Protocol Number: M16-000 Start Date*: 2017-08-23
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10013099 Disease Crohns LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) GB (GB - no longer in EU/EEA) LV (Trial now transitioned) IE (Trial now transitioned) BG (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) EE (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) NO (Trial now transitioned) LT (Trial now transitioned) BE (Trial now transitioned) HR (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005995-14 Sponsor Protocol Number: 3133K1-3001-WW(B2521002) Start Date*: 2009-05-29
    Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disea...
    Medical condition: Alzheimer Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-015929-37 Sponsor Protocol Number: 1001 Start Date*: 2010-09-02
    Sponsor Name:Andromeda Biotech Ltd, 42 Hayarkon st, Yavne, 81227, Israel
    Full Title: A PHASE III, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF DIAPEP277® IN NEWLY DIAGNOSED TYPE 1 DIABETES SUBJECTS
    Medical condition: Type I diabetes
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) DE (Completed) IT (Completed) AT (Completed) CZ (Completed) LT (Completed) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000255-12 Sponsor Protocol Number: D5676C00001 Start Date*: 2020-09-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b, Multicentre, Randomised, Double-blind, Placebo controlled, and Open-label Comparator Study of Cotadutide in Participants Who Have Chronic Kidney Disease with Type 2 Diabetes Mellitus
    Medical condition: Chronic Kidney Disease with Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000892-33 Sponsor Protocol Number: ZP4207-17086 Start Date*: 2019-01-29
    Sponsor Name:Zealand Pharma A/S
    Full Title: A phase 3, randomized, double-blind, placebo- and active-controlled, parallel-arm trial to assess the efficacy, safety, and pharmacokinetics of dasiglucagon relative to placebo and GlucaGen® when a...
    Medical condition: Type 1 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2010-023101-35 Sponsor Protocol Number: CJI-202 Start Date*: 2011-02-11
    Sponsor Name:Sequel Pharmaceuticals Inc.
    Full Title: TUNDRA-AF: A mulTi-center, randomized, doUble-bliNded, placebo-controlled Dose-escalating study of the effects of K201 on the RestorAtion of sinus rhythm in subjects with symptomatic Atrial Fibri...
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003658 Atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001061-29 Sponsor Protocol Number: NN8630-1823 Start Date*: 2008-06-17
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, double blind, placebo-controlled, multiple dose, dose-escalating, sequential dose group trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of pegylated lo...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056438 Growth hormone deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-002538-32 Sponsor Protocol Number: MY-1-2015 Start Date*: 2015-10-26
    Sponsor Name:Medicinsk Forskningsafsnit, Regionshospitalet Holstebro (Department of Medical Research, Regional Hospital Holstebro)
    Full Title: THE EFFECT OF ACYL-GHRELIN ON SODIUM REABSORPTION VIA ENAC IN HEALTHY VOLUNTEERS IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER STUDY
    Medical condition: The physiological responses to Acyl-ghrelin-injection on the sodium reabsorption via ENaC in healthy subjects.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000180-13 Sponsor Protocol Number: HAT1 Start Date*: 2015-04-22
    Sponsor Name:Medisch Centrum Haaglanden
    Full Title: The value of a High-Volume Image-Guided Injections (HVIGI) in chronic midportion Achilles tendinopathy: a double-blind, placebo-controlled, randomised clinical trial
    Medical condition: Chronic midportion Achilles tendinopathy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001385-16 Sponsor Protocol Number: BACTstudy Start Date*: 2019-11-22
    Sponsor Name:Clinic for Medicine and rehabilitation, Nord-Trondelag Trust (HNT)
    Full Title: Botulinum toxin A in frequent and chronic tension-type headache. A double blind, randomized, placebo-controlled cross-over trial
    Medical condition: Frequent and chronic tension-type headache
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004809-31 Sponsor Protocol Number: CAIN457R12301 Start Date*: 2021-09-24
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg administered subcutaneously versus placeb...
    Medical condition: giant cell arteritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10047065 - Vascular disorders 10018250 Giant cell arteritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) BG (Trial now transitioned) SE (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000568-41 Sponsor Protocol Number: GS-US-417-0301 Start Date*: 2016-10-11
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to ...
    Medical condition: Moderately to severely active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) GB (Completed) BE (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BG (Completed) PL (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-004766-35 Sponsor Protocol Number: RD.06.SPR.204358 Start Date*: 2022-06-06
    Sponsor Name:Galderma S.A.
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects with Chronic Kidney Disease with Associated Severe Pruritus
    Medical condition: Chronic Kidney Disease Associated Severe Pruritus
    Disease: Version SOC Term Classification Code Term Level
    24.1 10040785 - Skin and subcutaneous tissue disorders 10037087 Pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003086-34 Sponsor Protocol Number: CAIN457A3301 Start Date*: 2013-12-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Ind...
    Medical condition: Moderate to severe chronic palmoplantar pustular psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10040785 - Skin and subcutaneous tissue disorders 10037575 Pustular psoriasis PT
    16.1 10040785 - Skin and subcutaneous tissue disorders 10037158 Psoriasis palm & soles LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) AT (Completed) ES (Completed) DE (Completed) BE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003738-25 Sponsor Protocol Number: ESR-16-12160/UKE-DapEx-001 Start Date*: 2017-12-28
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: A 28-week, multi-center randomized, double-blind, placebo-controlled study to evaluate the potential of Dapagliflozin plus Exenatide in combination with high-dose intensive insulin therapy compared...
    Medical condition: Obese insulin-resistant patients with Type 2 Diabetes mellitus (T2DM) and inadequate glycemic control (HbA1c ≥ 8.0% and ≤ 11.0%)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001611-24 Sponsor Protocol Number: CAIN457ADE16 Start Date*: 2021-07-26
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A two-year multi-center Phase 3 study to investigate the efficacy and safety of secukinumab in adult patients with active, moderate to severe thyroid eye disease (ORBIT), with a randomized, paralle...
    Medical condition: Active, moderate to severe thyroid eye disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10060742 Endocrine ophthalmopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 22  23  24  25  26  27  28  29  30  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 19:01:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA